Future Fund LLC Takes $1.13 Million Position in Guardant Health, Inc. $GH

Future Fund LLC purchased a new position in Guardant Health, Inc. (NASDAQ:GH) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 21,730 shares of the company’s stock, valued at approximately $1,131,000.

A number of other institutional investors have also added to or reduced their stakes in the company. Teacher Retirement System of Texas bought a new stake in shares of Guardant Health during the 1st quarter valued at $866,000. Envestnet Asset Management Inc. lifted its position in Guardant Health by 136.6% during the 1st quarter. Envestnet Asset Management Inc. now owns 27,497 shares of the company’s stock valued at $1,171,000 after acquiring an additional 15,877 shares during the period. Cerity Partners LLC boosted its stake in Guardant Health by 6.4% during the first quarter. Cerity Partners LLC now owns 145,475 shares of the company’s stock worth $6,197,000 after acquiring an additional 8,725 shares in the last quarter. Xponance Inc. grew its holdings in Guardant Health by 6.8% in the first quarter. Xponance Inc. now owns 9,116 shares of the company’s stock worth $388,000 after purchasing an additional 582 shares during the period. Finally, Emerald Mutual Fund Advisers Trust bought a new position in shares of Guardant Health during the first quarter valued at approximately $13,942,000. Institutional investors own 92.60% of the company’s stock.

Guardant Health Price Performance

Shares of NASDAQ:GH opened at $96.72 on Friday. Guardant Health, Inc. has a 1 year low of $28.20 and a 1 year high of $100.22. The company has a market cap of $12.19 billion, a P/E ratio of -30.13 and a beta of 1.56. The stock’s fifty day moving average price is $67.52 and its 200-day moving average price is $55.05.

Guardant Health (NASDAQ:GH) last issued its earnings results on Wednesday, October 29th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.26). The business had revenue of $265.20 million during the quarter, compared to analyst estimates of $235.72 million. The business’s revenue was up 38.5% compared to the same quarter last year. During the same period last year, the business posted ($0.88) earnings per share. Guardant Health has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Guardant Health, Inc. will post -2.9 earnings per share for the current year.

Insider Activity at Guardant Health

In related news, Director Medina Manuel Hidalgo sold 2,165 shares of the stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $54.16, for a total transaction of $117,256.40. Following the transaction, the director owned 851 shares in the company, valued at $46,090.16. This represents a 71.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Helmy Eltoukhy sold 300,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $59.45, for a total transaction of $17,835,000.00. Following the completion of the sale, the chief executive officer owned 2,123,499 shares in the company, valued at $126,242,015.55. This represents a 12.38% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 302,691 shares of company stock valued at $17,984,628 over the last three months. 6.10% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

GH has been the topic of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a research report on Wednesday, October 8th. Cowen reissued a “buy” rating on shares of Guardant Health in a report on Thursday, October 30th. Raymond James Financial raised their price target on Guardant Health from $59.00 to $61.00 and gave the company an “outperform” rating in a report on Thursday, July 31st. Evercore ISI upped their price target on shares of Guardant Health from $68.00 to $90.00 and gave the stock an “outperform” rating in a research note on Thursday, October 30th. Finally, BTIG Research increased their price objective on shares of Guardant Health from $80.00 to $100.00 and gave the company a “buy” rating in a research report on Thursday, October 30th. Twenty-three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Guardant Health currently has a consensus rating of “Moderate Buy” and an average target price of $77.14.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.